Steven Innaimo is a seasoned drug developer who brings more than 30 years of diverse operational experience from the large pharma, biotech, and contract research industries. Prior to joining OBI, Steve directed the development of Portage Biotech Inc.’s unique immuno-oncology portfolio as VP of Project Management and Clinical Operations. Earlier experience includes leadership roles at Covance as Head of the Global Project Management Office and nearly 23 years at Bristol-Myers Squibb in roles of increasing responsibility within Discovery, Oncology Project Management and Clinical Operations. During his tenure at BMS, Steve held pan-therapeutic responsibilities across the portfolio and was integrally involved in shaping and managing the drug development governance process. Steve directly managed or provided operational oversight for key BMS value driver assets including YERVOY®, OPDIVO®, ERBITUX®, TAXOL®, BARACLUDE® and several others. He has successfully shepherded multiple therapies to initial and post-marketing registrations globally. Steve began his R&D career as a molecular biologist focusing on Hepatitis B Virus at TargeTech Inc. He holds a B.S. in Molecular Biology, a M.S. in Endocrinology from the University of Connecticut, and a Project Management Certificate from Boston University.